ESC Scorching Lines: 1st True Information On Promising Novartis Heart Failure Drug

The initial true particulars about the a lot-anticipated novel new heart failure drug from Novartis Novartis will kick off this year’s Sizzling Line sessions at the yearly meeting of the European Society of Cardiology in Barcelona, Spain. The meeting runs from August 30 right up until September three.

As I have previously reported, the PARADIGM-HF trial was stopped since of a extremely statistically important reduction in cardiovascular mortality in individuals taking LCZ696 (a novel, 1st-in-class Angiotensin Receptor Neprilysin Inhibitor) instead of the existing gold common of remedy, an ACE ACE inhibitor. Until we see the information it is unattainable to attain any conclusions, but it should be mentioned that there would be huge clinical and organization implications if a new drug  becomes a normal of therapy for millions of people with heart failure.

One more presentation that will likely entice a whole lot of curiosity is the SIGNIFY trial with the drug ivabradine, which is marketed in Europe by Servier and is below improvement in the US by Amgen. As I have previously reported, the European Medicines Agency mentioned that it has started out a assessment of the drug primarily based on troubling findings from the trial.

Also confident to entice interest will be two presentations on the new PCSK9 inhibitor alliorcumab beneath development by Sanofi and Regeneron. Chris Cannon will current benefits of the Odyssey Combo II study in high threat patients with inadequately managed hypercholesterolemia on maximally tolerated daily statin. Michel Farnier will present results of the ODYSSEY FH I and FH II scientific studies in patients with heterozygous familial hypercholesterolemia not adequately managed with existing lipid-decreasing treatment.

Right here is the complete record of Sizzling Line trials:

Hot Line: Cardiovascular ailment: novel therapies

• 31 Aug 08:thirty – ten:20


• Chairpersons: Mariell JESSUP (Philadelphia, US), Hector BUENO (Madrid, ES)

08:30 Benefits of the Prospective comparison of ARNI with ACEI to Determine Impact on Worldwide Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Milton PACKER (Dallas, US)

• Discussant: Michel KOMAJDA (Paris, FR)

08:48 A randomized managed trial of vagal stimulation for the remedy of systolic heart failure: NEural Cardiac Therapy foR Heart Failure (NECTAR-HF) Faiez ZANNAD (Vandoeuvre Les Nancy, FR)

• Discussant: John CAMM (London, GB)

09:06 Impact of ferric carboxymaltose on functional capacity in individuals with heart failure and iron deficiency (Verify-HF) Piotr PONIKOWSKI (Wroclaw, PL)

• Discussant:  Harry CRIJNS (Maastricht, NL)

09:24 Cardiac resynchronization treatment with a novel quadripolar lead decreases problems at 6 months: preliminary benefits of the More-CRT trial Giuseppe BORIANI (Bologna, IT)

• Discussant: John CLELAND (London, GB)

09:42 Colchicine for Submit- operative Pericardial Effusion: The post-operative pericardial effusion (POPE-two) Study. A multicenter, double-blind, randomized trial Philippe MEURIN (Villeneuve-St.-Denis, FR)

• Discussant: Jae K OH (Rochester, US)

10:00 COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial) Massimo IMAZIO (Torino, IT)

• Discussant: Stavros V KONSTANTINIDES (Mainz, DE)

Sizzling Line: Coronary artery condition and lipids

• 31 Aug 16:thirty – 18:00 Miscellaneous Hot Line Barcelona – Central Village


• Chairpersons: John Gordon HAROLD (Los Angeles, US), Fausto Jose PINTO (Lisbon, PT)

sixteen:thirty The Stabilization Of pLaques Utilizing Darapladib-Thrombolysis in Myocardial Infarction 52 (Reliable-TIMI 52) trial: Main Benefits Michelle O’DONOGHUE (Boston, US)

• Discussant: Robert M CALIFF (Durham, US)

sixteen:48 Ivabradine in patients with steady coronary artery ailment without clinical heart failure: The final results of SIGNIFY Kim FOX (London, GB)

• Discussant: Jean-Pierre BASSAND (Thise, FR)

17:06 Efficacy and security of alirocumab in higher cardiovascular danger individuals with inadequately managed hypercholesterolaemia on maximally tolerated everyday statin: final results from the ODYSSEY COMBO II examine Christopher Paul CANNON (Boston, US)

• Discussant: Thomas Felix LUSCHER (Zurich, CH)

17:24 Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately managed with recent lipid-reducing treatment: results of ODYSSEY FH I and FH II scientific studies Michel FARNIER (Dijon, FR)

• Discussant: Thomas Felix LUSCHER (Zurich, CH)

17:42 The distinctions of the effects on lipid-lowering actions and glucose metabolisms in between rosuvastatin and atorvastatin in Japanese diabetic individuals with hyperlipidemia Hisao OGAWA (Kumamoto, JP)

• Discussant: John CHAPMAN (Paris, FR)

Hot Line: Heart failure: gadgets and interventions

• 1 Sep eleven:00 – twelve:50 Miscellaneous Hot Line Barcelona – Central Village


• Chairpersons: Hisao OGAWA (Kumamoto, JP), Panagiotis VARDAS (Heraklion, GR)

eleven:00 Randomized comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a resilient polymer everolimus-eluting stent for percutaneous coronary revascularization Thomas PILGRIM (Bern, CH)

• Discussant review Patrick SERRUYS (Rotterdam, NL)

eleven:18 Autonomic regulation therapy for the improvement of left ventricular function and heart failure signs and symptoms: The ANTHEM-HF Research Inder ANAND (Minneapolis, US)

• Discussant overview Gerhard HINDRICKS (Leipzig, DE)

11:36 Biventricular pacing for atrIo-ventricular BlOck to Stop cArdiaC dEsynchronization Jean-Jacques BLANC (Brest, FR)

• Discussant assessment Patrick SCHAUERTE (Berlin, DE)

eleven:54 Comparison of appropriate ventricular septal pacing and right ventricular pacing in patinets acquiring a CRT-D Christophe LECLERCQ (Rennes, FR)

• Discussant review Jagmeet SINGH (Boston, US)

twelve:12 Optimal technique and outcomes of catheter ablation of persistent atrial fibrillation: Outcomes of the Potential, Randomized STAR AF 2 Trial Atul VERMA (Newmarket, CA)

• Discussant review Paulus KIRCHHOF (Birmingham, GB)

12:thirty EuroEco (European Overall health Financial Trial on House Monitoring in ICD Sufferers): a provider viewpoint on comply with-up costs and net financial affect of remote monitoring in 6 European nations Hein HEIDBUCHEL (Leuven, BE)

• Discussant review Carina BLOMSTROM-LUNDQVIST (Uppsala, SE)

Hot Line: Myocardial Infarction

• one Sep 16:thirty – 18:00 Miscellaneous Sizzling Line Barcelona – Central Village


• Chairpersons: Lars WALLENTIN (Uppsala, SE), Karl-Heinz KUCK (Hamburg, DE)

sixteen:30 Comprehensive versus Lesion only Principal -PCI Trial (CvLPRIT): Deal with the infarct related artery only or all lesions Anthony H GERSHLICK (Leicester, GB)

• Discussant review Shamir R MEHTA (Hamilton, CA)

16:48 In-ambulance versus in-cath lab administration of ticagrelor in STEMI individuals transferred for major PCI: the randomized, double-blind ATLANTIC research Gilles MONTALESCOT (Paris, FR)

• Discussant review Paul Wayne ARMSTRONG (Edmonton, CA)

17:06 The British Heart Basis Fractional Flow Reserve versus Angiography in Guiding Management to Optimise Outcomes in Non-ST-Section Elevation Myocardial Infarction Colin BERRY (Glasgow, GB)

• Discussant overview Bernard DE BRUYNE (Aalst, BE)

17:24 Nitric oxide for inhalation to decrease reperfusion damage in acute st-elevation myocardial infarction

• Discussant evaluation Michael MARBER (London, GB)

17:42 Impact of intravenous TRO40303 as an adjunct to principal percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the MITOCARE review Dan ATAR (Oslo, NO)

• Discussant assessment Hans Erik BOTKER (Aarhus N, DK)

Sizzling Line: Coronary artery disease and atrial fibrillation

• 2 Sep 11:00 – 12:30 Miscellaneous Sizzling Line Barcelona – Central Village


• Chairpersons: Keith FOX (Edinburgh, GB)

eleven:00 Perioperative statin treatment in cardiac surgical treatment for the prevention of atrial fibrillation and perioperative myocardial harm: the Statin Treatment In Cardiac Surgical procedure (STICS) Trial Barbara CASADEI (Oxford, GB)

• Discussant evaluation Paulus KIRCHHOF (Birmingham, GB)

eleven:18 The X-VERT Trial: A comparison of oral rivaroxaban once everyday with dose-adjusted Vitamin K Antagonists in individuals with nonvalvular atrial fibrillation undergoing elective cardioversion Riccardo CAPPATO (San Donato Milanese, IT)

• Discussant overview Christoph BODE (Freiburg, DE)

eleven:36 Recurrence of arrhythmia following quick-term oral AMIOdarone right after CATheter ablation for atrial fibrillation: A double-blind, randomized, placebo-controlled research Stine DARKNER (Copenhagen, DK)

11:54 Impact of large-intensity statin treatment on atherosclerosis in patients with ST-elevation myocardial infarction: Final results of the prospective, longitudinal intravascular ultrasound adhere to-up review Lorenz RABER (Bern, CH)

• Discussant overview Steven E NISSEN (Cleveland, US)

12:twelve IMPI Steroid Review: A Trial of Adjunctive Prednisolone in Tuberculous Pericarditis Bongani Mawethu MAYOSI (Cape Town, ZA)

ESC Scorching Lines: 1st True Information On Promising Novartis Heart Failure Drug